Recent studies demonstrate that disrupting the CCNB1–CDK1 complex effectively retards tumorigenesis [46, 47], positioning CDK1 as a promising therapeutic target in HCC [48, 49]. Here, CDK1 is linked to hepatocellular carcinoma.